Our Human Resources (HR) department manages all topics related to employer attractiveness, diversity and equal opportunities, and employee engagement. Our Health and Safety department, integrated into the Technical Operations area, takes care of all aspects of occupational health and safety (OHS).
Our aspiration is to give more hope to people with cancer and our employees are crucial to our success. In an industry such as biotechnology, where success largely depends on the innovation capability and commitment of our employees, aspects such as employee attraction, retention and engagement are critical success factors. The Management Board has made it a key priority to focus on employee engagement. Employee satisfaction is part of our short and long-term goals and this commitment is reflected in the inclusion of employee engagement as key performance indicator for the Long-Term Incentive Plan 2021 of the Management Board and selective employee groups becoming due in 2025. For the first time in 2021, we assessed Environmental, Social and Governance topics as part of our future annual employee survey to identify areas of improvement. MorphoSys is aiming for sustainable management practices across all three areas and moving forward we will measure progress annually.
With the acquisition of Constellation Pharmaceuticals our workforce has grown to more than 7001 employees at the end of 2021. As a combined company, we are focusing on the needs of patients and are inspired by our company values – Courage, Urgency, Innovation and Collaboration – in everything we do. Our employer proposition is based on our strong commitment to patients and our employees.
With the global COVID-19 pandemic, the biotech sector has been in focus. New investments are being made in the pharmaceutical industry, worldwide, and particularly in the U.S. and Germany, the main markets in which MorphoSys operates. To engage qualified professionals across scientific, medical, commercial and enabling functions, MorphoSys is keen to articulate a value proposition and providing a working environment of personal growth, aligned with the Company’s objective to become a leader in hematology/oncology. This is embedded in our new employee program ESPRIT, “The Spirit of MorphoSys,” as well as the New Work concept, providing attractive working models aligned with current demands for flexibility and hybrid approaches, both launched in 2021. As we want to be well positioned for our growth, we have further expanded our social media presence by making more content available on LinkedIn and selective portals, and are working continuously and with focus on workforce planning and securing the talent to enable our strategic goals. Our workforce planning efforts were focused on understanding the synergy potential after the acquisition of Constellation Pharmaceuticals, as well as staffing new areas to drive automatization and digitalization.
In 2021 the Company’s Life and Job pages in LinkedIn were visited by more than 13,000 visitors. 54% of the visitors viewed the Jobs area and 39% of new hires visited the Life or Job pages, showing a high degree of success in our employer branding and external outreach. We are committed to transparency and equal opportunities in our job vacancies, development of employees, and a positive working environment. All our open job opportunities are advertised worldwide.
In 2021, we launched a new initiative “ESPRIT” in MorphoSys AG and MorphoSys US Inc., our new performance philosophy to build a culture of growth and established new people practices that are aligned with our values. This includes priority setting, ongoing feedback, rewards and recognition, and value-based leadership. As part of the integration process, Constellation Pharmaceuticals employees will also be part of the ESPRIT program from 2022 onwards. MorphoSys’ employer attractiveness strategy builds upon creating a modern and appealing working environment for candidates who are looking to make a difference and bring more hope to people with cancer. The ESPRIT program is one of the main pillars and embeds our ways of working at MorphoSys.
MorphoSys is focused on attracting skilled employees in all technical areas as well as leadership competencies, since leadership is directly connected to employee engagement, sustainable management and our overall Company success. Our Global Leadership Group is comprised of more than 10% leaders from all departments across the Company, worked with the Management Board on enabling the implementation of our strategy, balancing a growing organizational structure with reduced complexity and cross-functional collaboration and the launch and implementation of ESPRIT. We view a leadership environment characterized by strong values, empowerment and accountability as essential to achieving our goals.
Diversity and Equal Opportunities
Valuing diversity and ensuring equal opportunities are firmly anchored in our corporate culture. We believe that every single colleague needs to be heard and plays an important role in contributing to our success. We therefore are committed to policies that do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, gender, gender identity, national origin, age, sexual orientation, marital or protected veteran status, medical condition, pregnancy, disability or any other legally protected status. We aim for an open working environment where creativity and innovation can flourish.
In 2020 our CEO Jean-Paul Kress, M.D., signed the “CEO Pledge for a More Equitable and Inclusive Life Sciences Industry” initiated by the Massachusetts Biotechnology Council to demonstrate the commitment of MorphoSys and the whole biotechnology industry to diversity and inclusion.
Our diversity concept pursuant to the German Commercial Code (HGB) can be found in our ›› Corporate Governance Report.
It is paramount to MorphoSys to create a culture of collaboration and inclusion of different perspectives, where everyone can contribute and bet at their best.
At the end of 2021, 59% of employees were women, and 58% of executives3 were women. The proportion of women in the Company’s workforce thus remains at a consistently high level. In addition, we proudly employed individuals of 43 different nationalities, which adds to our identity as a truly global organization. For a comparison with the 2020 figures, it should be taken into account that Constellation Pharmaceuticals is now included in the 2021 figures.